marc yates

* Responsible for calling on Hospital Social Workers, Hospitalists, and Orthopedic Surgeons to increase census/sales for a short and long-term rehabilitation nursing facility. * Increased Census from 66% occupancy to 90% occupancy in 1 year. * Reached 100% occupancy in second year.

* Responsible for increasing market share in the Buffalo, Rochester, Elmira and Syracuse areas, for a sales contract through Berlex Laboratories. * Accomplished a quota attainment that was in the top 20% of sales force. * Implemented sales strategies toward Pulmonologists on new diagnostic imaging tool in characterizing lung cancer. * Detailed over 75 Cardiologists and pharmacies on new Anti-Arrhythmic agent branded BetapaceAF.

* Established new advertising accounts and surpassed quarterly quotas of $50,000 by 25%. * Ranked #1 sales representative for Internet Web Sites in 1999. * Recipient, 1999 “Rookie of the Year” Award.

* Responsible for switching over long distance carrier for small and midsize businesses in the greater Detroit area. * Performed 30-40 cold calls daily for mid-size communication company. * Chosen by District Manager to attend Dale Carnegie Seminar and Brian Tracy Sales Seminar, 1997.

* Female Healthcare Division – Erie, PA * Ranked 22/369 in the country for market share growth for Yasmin, an oral contraceptive. * Successfully launched Yaz, a low-dose Yasmin formulation. * Achieved 61% sales growth for Mirena. Multiple Sclerosis Division – Rochester, NY * Worked with the Vice President of R&D to facilitate relationships with the key thought leaders at the University of Rochester – Neurological and Multiple Sclerosis Center – and integrate the center into ongoing research and new studies for the treatment of Relapsing-Remitting Multiple Sclerosis. * President Circle Winner of Outstanding Performance in 2004 for the greatest percentage increase in market share for Betaseron, an interferon therapy for Multiple Sclerosis. * Attained Preferred Formulary Status for Refludan, an in-patient hospital therapy indicated for Heparin-Induced Thrombocytopenia, at the University of Rochester – Strong Memorial Hospital. * Achieved 167% of NRx sales goal for Refludan. * Chosen by District Manager at Berlex Laboratories to attend Stephen R. Covey Seminar, “What Matters Most”.

* Responsible for business planning, strengthening advertising and marketing positions in order to increase sales/census for a short & long-term rehabilitation nursing facility. * Detailed physical therapy, occupational, speech therapy services and effectiveness to Social Workers, Family Practice, Internal Medicine, and Orthopedic Surgeons. * Increased Census/Sales from 66% occupancy to 90% occupancy in 1 year. * Reached 100% occupancy in August 2011.

* Responsible for selling and increasing market share for 3 key insulin products: Levemir, Novolog Mix 70/30, and Novolog. * Responsible for educating Primary Care and Internal Medicine Physicians on new ADA guideliines and treatment algorithms for Type 2 Diabetes. * In 2007, nominated for Rookie of the Year based on % market share growth.

* Successfully worked with teammates to launch Bydureon, an injectable GLP-1 agonist for Type 2 Diabetes. * Regional contest winner for attaining the highest market share in March and July of 2012. * Ranked #1 out of 12 in Bydureon NRx sales in the 3rd quarter of 2012. * Hired by Bristol Meyer-Squibb in December 2012 to continue the successful launch of Bydureon, and increase market share for a complete portfolio of DPP-4 inhibitors for Type 2 Diabetes * Onglyza and Kombiglyze.

* Previously Bristol-Myer’s Squibb Diabetes Division (acquisition 2014). Began as inVentiv Health contract team (2012) * Established long-term relationships with Endocrinologists, Internal Medicine, and Primary Care Physicians through providing evidence based information resulting in increased market share of a GLP-1 Agonist product for Type 2 Diabetes. * 136% NRx goal attainment in 2016. * Increased market share for oral portfolio of therapies including Onglyza, Kombiglyze, and Farxiga. * Successfully launched Farxiga, an oral SGLT-2 inhibitor indicated for the treatment of Type 2 Diabetes and Bydureon, a once-weekly GLP-1 injectable for Type 2 Diabetes. * Regional contest winner for attaining the highest market share increase for Bydureon NRx. * Ranked #1 out of 12 in district for Bydureon NRx sales.

Activities and Societies: Phi Sigma Kappa